Adverse drug reactions to biologics;Unerwünschte Arzneimittelreaktionen auf Biologika

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 6, 2010, Pages 411-426

  Scherer, Kathrin ^a   Spoerl, David ^a   Bircher, Andreas J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anaphylaxis; Biologics; Classification; Exanthema; Hypersensitivity; Infusion reaction; Injection site reaction

Indexed keywords

ABATACEPT; ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MEPOLIZUMAB; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; PERTUZUMAB; RANIBIZUMAB; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; RILONACEPT; RITUXIMAB; SIMPONI; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VISILIZUMAB;

ACUTE KIDNEY TUBULE NECROSIS; ALLERGY; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTHRALGIA; ATOPY; AUTOIMMUNE DISEASE; BLEEDING; BRAIN DISEASE; BULLOUS DERMATITIS; CHURG STRAUSS SYNDROME; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEMYELINATING DISEASE; DIARRHEA; DRUG HYPERSENSITIVITY; ECZEMA; EDEMA; ERYTHEMA; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEART FAILURE; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; LYMPHADENOPATHY; LYMPHOCYTOSIS; LYMPHOMA; MENINGOCOCCOSIS; NEPHROTIC SYNDROME; PROTEINURIA; PRURITUS; PSORIASIS; RASH; REVIEW; SERUM SICKNESS; SINGLE DRUG DOSE; SKIN TEST; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUMOR LYSIS SYNDROME; URTICARIA; VASCULITIS; VEIN OCCLUSION;

EID: 77953173497     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2010.07339.x     Document Type: Review

References (58)

1. Calogiuri G, Ventura MT, Mason L, Valacca A, Buquicchio R, Cassano N, Vena GA. Hypersensitivity reactions to last generation chimeric, humanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des 2008 14 : 2883 2891.
2. Treudler R. New drug therapies and their effect on the skin. J Dtsch Dermatol Ges 2009 7 : 623 626.
3. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W-H. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges 2007 5 : 762 768.
4. Rott S, Mrowietz U. The use of infliximab in dermatology. J Dtsch Dermatol Ges 2007 5 : 655 660.
5. Weber RW. Adverse reactions to biological modifiers. Curr Opin Allergy Clin Immunology 2004 4 : 277 283.
6. Bremmer M, Deng A, Gaspari A. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1. Dermatitis 2009 20 : 182 192.
7. Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008 4 : 1537 1549.
8. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006 61 : 912 920.
9. Scherer K, Spoerl D, Bircher AJ. Réactions indésirables aux immunobiologiques. In : Eurotext ÉJL (ed Progrès en Dermato-Allergologie. Bordeaux 2009.
10. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008 300 : 1887 1896.
11. Saxon A. Who-mab's on first and what-cept's on second. I don't know -Third base Clin Immunol 2008 127 : 267.
12. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006 24 : 274 280.
13. Ballow M. Ximab this and -zumab that Has the magic bullet arrived in the new millennium of medicine and science? J Allergy Clin Immunol 2005 116 : 738 743.
14. Pichler WJ, Campi P. Adverse Side Effects to Biological Agents. In : Pichler WJ (ed Drug Hypersensitivity.
15. Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007 12 : 601 609.
16. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008 13 : 725 732.
17. Arnold DF, Misbah SA, Commins SP, Mirakhur B, Platts-Mills TAE. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3- Galactose. N Engl J Med 2008 358 : 2735 2736.
18. Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TAE. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose. N Engl J Med 2008 358 : 1109 1117.
19. van Der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001 115 : 807 811.
20. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 373 (9664 633 640.
21. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008 135 : 1130 1141.
22. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med 2006 355 : 1018 1028.
23. Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists. Curr Opin Allergy Clin Immunol 2007 7 : 393 403.
24. Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC, Yang CH, Hung SI, Chung WH. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 2008 26 : 2779 2780.
25. Scheinfeld N. Alefacept: Its safety profile, off-label uses, and potential as part of combination therapies for psoriasis. Journal of Dermatological Treatment 2007 18 : 197 208.
26. Ochsenbein AF. Monoklonale Antikörper als therapeutische Substanzen. Schweiz Med Forum 2008 8 : 140 143.
27. Pichler WJ. Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell Activation. In : Pichler WJ (ed). Drug Hypersensitivity.
28. Bremmer M, Deng A, Gaspari A. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2. Dermatitis 2009 20 : 243 256.
29. Homey B. Acute side effects of the therapeutic use of biologics. How and why? Hautarzt 2008 59 : 438.
30. Cox L, Platts-Mills TAE, Finegold I, Schwartz LB, Simons FER, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007 120 : 1373 1377.
31. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007 120 : 972 973.
32. Lieberman P. The unusual suspects: A surprise regarding reactions to omalizumab. Allergy Asthma Proc 2007 28 : 259 261.
33. Kalpaklioglu A, Kavut A, Erdemoglu A. Desensitization in interferonbeta1a allergy: a case report. Int Arch Allergy Immunol 2009 149 : 178 180.
34. Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, Colburn N. Anaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs. Ann Pharmacotherapy 2009 43 : 967 972.
35. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 2008 18 : 335 342.
36. Bircher AJ, Czendlik C, Langauer Messmer S, Müller P, Howald H. Acute urticaria from subcutaneous recombinant hirudin. Evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol 1996 98 : 994 996.
37. Bircher AJ, Hedin H, Berglund A. Probable grade IV dextran-induced anaphylactic reaction despite hapten inhibition. J Allergy Clin Immunol 1995 95 : 633 634.
38. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 608. (Pubitemid 36204954)
39. Moneret-Vautrin DA, Morisset M, Vignaud JM, Kanny G. T cell mediated allergy to abciximab. Allergy 2002 57 : 269 270.
40. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. Journal of Dermatological Treatment 2004 15 : 280 294.
41. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, Histological, and Immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor-α Receptor: Fc fusion protein. Arch Dermatol 2001 137 : 893 899.
42. Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 2008 63 : 138 139.
43. Vila AT, Puig L, Fernández-Figueras MT, Laiz AM, Vidal D, Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Brit J Dermatol 2005 153 : 417 423.
44. Regula CG, Hennessy J, Clarke LE, Adams DR, Ioffreda MD, Graber EM, Helm KF. Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol 2008 59 : S25 S27.
45. Marcollo Pini A, Kerl K, Kamarachev J, French LE, Hofbauer GFL. Interstitial granulomatous drug reaction following intravenous ganciclovir. Brit J Dermatol 2008 158 : 1391 1393.
46. Zukiwski AA, David CL, Coan J, Wallace S, Gutterman JU, Mavligit GM. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer 1990 65 : 1521 1524.
47. Shulman KL, Thompson JA, Benyunes MC, Winter TC, Fefer A. Adverse reactions to intravenous contrast media in patients treated with interleukin-2. J Immunother Emphasis Tumor Immunol 1993 13 : 208 212.
48. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006 20 : 5 13.
49. Paltiel M, Gober LM, Deng A, Mikdashi J, Alexeeva I, Saini SS, Gaspari AA. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Archives of Dermatology 2008 144 : 1190 1194.
50. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007 28 : 313 319.
51. Domm A. A patient's reaction to infliximab. Ann Allergy Asthma Immunol 2003 90 : 298 301.
52. Hawkins C, Gatenby P, McGill D. Severe hypotension complicating primary angioplasty: allergy to abciximab. Allergy 2003 58 : 688 689.
53. Leonard PA, Woodside KJ, Gugliuzza KK, Sur S, Daller JA. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation 2002 74 : 1697 1700.
54. Bircher AJ, Scherer K. Arzneimittelhy-persensitivität - unerwünschte Arzneimittelreaktionen durch Biologika. In Kongress der DGAKI und AEDA. Erfurt, Dustri Verlag, im Druck, 2009.
55. Lelong J, Duburque C, Fournier C, Colombel J-F, Desreumaux P, Tonnel A-B, Wallaert B. [Desensitisation to infliximab in patients with Crohn's disease]. Rev Mal Respir 2005 22 : 239 246.
56. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 2006 6 : 271 277.
57. Jerath MR, Kwan M, Kannarkat M, Mirakhur B, Carey L, Valgus J, Platts-Mills TA, Tarrant TK. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol 2009 123 : 260 262.
58. Brennan PJ, Bouza TR, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009 124 : 1259 1266.